Skip to main content
HELP
NASDAQ Life Sciences

Chief Growth Officer Discloses 5.8% Stake, Including $1.04M Open Market Purchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$12.835
Mkt Cap
$1.39M
52W Low
$3.76
52W High
$14.35
52W Position info
241% above low
Off High info
11% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

HELP has more than doubled off its 52-week low of $3.76 on light trading volume (0.3× avg).

Summary

Cybin's Chief Growth Officer, Paul Glavine, has disclosed a 5.8% beneficial ownership stake, including a recent $1.04 million open market stock purchase, signaling high conviction.


Key Events · Ownership and Investor Activity · HELP

  • Chief Growth Officer's Significant Stake

    Paul Glavine, Cybin's Chief Growth Officer, reported beneficial ownership of 4,407,456 common shares, representing 5.8% of the company's outstanding stock.

  • $1.04 Million Open Market Purchase

    Glavine purchased 90,000 common shares on the open market at $11.5853 per share for a total of $1,042,677 on August 31, 2026. This transaction was previously disclosed in a concurrent Form 4 filing.

  • Restricted Stock Unit Award

    On September 1, 2026, Glavine was awarded 1,046,899 restricted stock units by the Issuer.


Analysis · HELP · Life Sciences

Paul Glavine, Cybin's Chief Growth Officer, has disclosed a significant beneficial ownership stake of 5.8% in the company. This includes a recent open market purchase of over $1 million, which represents a substantial portion of the company's market capitalization and signals strong personal conviction in Cybin's future, particularly ahead of key Phase 3 data. The filing also notes a recent award of restricted stock units.

How filings like this one have moved

In the 30 days to Sep 9, 2026, 44.3% of the 601 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HELP was trading at $12.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $14.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HELP - Latest Insights

HELP
Sep 09, 2026, 5:56 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $13.84
Real-time Price: $13.92 info
Change: +$0.080 (+0.58%) info
Market Cap: $1.39M info
HELP
Sep 09, 2026, 11:03 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $12.62
Real-time Price: $13.92 info
Change: +$1.30 (+10%) info
Market Cap: $1.39M info
HELP
Aug 14, 2026, 7:43 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $11.47
Real-time Price: $13.92 info
Change: +$2.45 (+21%) info
Market Cap: $1.39M info
HELP
Aug 14, 2026, 7:28 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $13.92 info
Change: +$2.32 (+20%) info
Market Cap: $1.39M info
HELP
Aug 03, 2026, 10:25 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.76
Real-time Price: $13.92 info
Change: +$6.16 (+79%) info
Market Cap: $1.39M info